← Leaderboards
Ferruccio Galbiati
University Of Pittsburgh At Pittsburgh
$5,815,432
Attributed
$5,815,432
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $695.3K · FY2005–21$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$5,815,432 · 5
By mechanism
R01$5,430,432 · 4
R56$385,000 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Divay Chandra$3,919,460
- Jonathan K. Alder$6,019,102
- Charles R Rinaldo$100,535,685
- Christopher J. Bakkenist$9,428,543
- Keith Michael Vogt$2,826,892
Others in their field
Top investigators on “Caveolin 1”
- William C. Sessa · Yale University$11,456,998
- Carlos Fernandez Hernando · Yale University$8,904,874
- Michael P Lisanti · Yeshiva University$7,412,885
- Jianjie Ma · Case Western Reserve University$7,343,295
- Thomas Michel · Brigham And Women'S Hospital$7,152,190
- Gang Bao · Georgia Institute Of Technology$6,888,075
Research focus
Caveolin 1SenescenceSignal TransductionCellsInvestigationInsightPathogenesisMolecularLinkMediatingLungIn VivoKnockout MiceSignaling MoleculeOxidative StressFibroblastsResponsePlayPathway InteractionsProteinsCell AgingUp-Regulation (Physiology)PrematureNovel Therapeutic Intervention
Grant awards (19)
Mechanisms that control the progression from premalignant lesions to adenocarcinomas in the lung$313,000
R01 · FY2021 · CA · contact PI
Mechanisms that control the progression from premalignant lesions to adenocarcinomas in the lung$313,000
R01 · FY2020 · CA · contact PI
Mechanisms that control the progression from premalignant lesions to adenocarcinomas in the lung$303,610
R01 · FY2019 · CA · contact PI
Mechanisms that control the progression from premalignant lesions to adenocarcinomas in the lung$312,500
R01 · FY2018 · CA · contact PI
Caveolin-1-mediated senescence, chronic inflammation and age-related lung disease$385,000
R01 · FY2017 · HL · contact PI
Mechanisms that control the progression from premalignant lesions to adenocarcinomas in the lung$310,250
R01 · FY2017 · CA · contact PI
Caveolin-1-mediated senescence, chronic inflammation and age-related lung disease$385,000
R01 · FY2016 · HL · contact PI
Caveolin-1-mediated senescence, chronic inflammation and age-related lung disease$385,000
R01 · FY2015 · HL · contact PI
Caveolin-1-mediated senescence, chronic inflammation and age-related lung disease$385,000
R56 · FY2014 · HL · contact PI
Caveolin 1: a novel modulator of the PP2A/ATM/p53 pathway$274,728
R01 · FY2013 · AG · contact PI
Caveolin 1: a novel modulator of the PP2A/ATM/p53 pathway$290,717
R01 · FY2012 · AG · contact PI
Caveolin 1: a novel modulator of the PP2A/ATM/p53 pathway$290,717
R01 · FY2011 · AG · contact PI
Caveolin 1: a novel modulator of the PP2A/ATM/p53 pathway$302,452
R01 · FY2010 · AG · contact PI
Caveolin 1: a novel modulator of the PP2A/ATM/p53 pathway$305,507
R01 · FY2009 · AG · contact PI
Role of Caveolin-1 in Cellular Senescence and Aging$244,344
R01 · FY2009 · AG · contact PI
Role of Caveolin-1 in Cellular Senescence and Aging$244,462
R01 · FY2008 · AG · contact PI
Role of Caveolin-1 in Cellular Senescence and Aging$249,567
R01 · FY2007 · AG · contact PI
Role of Caveolin-1 in Cellular Senescence and Aging$257,137
R01 · FY2006 · AG · contact PI
Role of Caveolin-1 in Cellular Senescence and Aging$263,441
R01 · FY2005 · AG